It is axiomatic that if the physician is to provide the best possible care for his patients he must continue, throughout his active professional life, to add to the knowledge he gained in medical school. During the past decade it has become increasingly apparent, however, that the practitioner cannot hope to familiarize himself with the overwhelming number of new drugs. All too often he is bewildered by a mass of information and misinformation. Studies of prescribing habits have shown that practicing physicians learn about new drugs primarily from the pharmaceutical industry via direct-mail advertising and detail men, by "corridor consultations" with colleagues, by attendance at medical meetings, and by a hurried perusal of one or more medical journals. In short, there is no concise, reliable source of information to which he can turn.
As part of a comprehensive drug evaluation and educational program, the AMA, through its Council on Drugs,